Clinical Trial: A Study of TRB191 in Patients With Extensive-stage Small Cell Lung Cancer

U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07908667) titled 'A Study of TRB191 in Patients With Extensive-stage Small Cell Lung Cancer' on Oct. 26.

Brief Summary: The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity (IG) and preliminary anti-tumor activity and to determine a recommended dose (RD) of TRB191 in patients with extensive-stage small cell lung cancer (ES-SCLC).

Study Start Date: Nov. 17

Study Type: INTERVENTIONAL

Condition: Extensive-stage Small Cell Lung Cancer

Intervention: DRUG: TRB191

Subcutaneous injection of TRB191

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Novartis Pharmaceuticals

Disclaimer: Curated by HT...